MilliporeSigma to Expand Oncology Research Offering at AACR 2017

MilliporeSigma have announced new innovations for oncology research at the American Association for Cancer Research Annual Meeting, April 2-5, in Washington, D.C. AACR attendees are encouraged to visit booth #931 to learn more about MilliporeSigma’s products and speak with company experts.

The expansion includes the launch of the new SMCxPRO™ instrument, which allows researchers to bind and quantify biomarkers in very low abundance, and profile cancer, and immune checkpoint proteins. The technology provides better outcomes for detecting various types of cancer and other diseases requiring ultra-high sensitivity and is less expensive than other technologies. It is just one product among a range of technologies that support in vitro models for discovery and in use in clinical settings.

“MilliporeSigma’s latest innovation is part of an entire suite of tools for predicting and characterizing cancer and driving therapeutics,” said Jason Apter, Head of Research Solutions Strategic Marketing & Innovation at MilliporeSigma. “Early cancer detection translates directly into options for patients and better outcomes for many types of cancer. We are committed to empowering scientists and researchers by giving them the technologies they need to develop new tools accelerate access to better health.”

MilliporeSigma offers dozens of products that predict cancer, including biomarkers, antibodies, as well as products for novel target discovery, including the Sanger CRISPR libraries. These CRISPR libraries are the first of its kind, providing a collection of individual clones designed to knock out every known human and mouse protein-coding gene using the CRISPR system. MilliporeSigma’s advancements in gene editing tools like CRISPR are helping to accelerate discovery and manufacturing of new treatments for difficult to treat conditions.